Trials of a new cholesterol-lowering pill have shown promising results for people with heterozygous familial ...

Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about ...

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an ...

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an ...

Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% ...

On Oct. 10, the FDA classified the recalled prescription medication as a Class II recall. The risk classification from the ...

A RECENT randomised clinical trial investigated whether the combination of simvastatin and rifaximin could prevent severe complications in patients with decompensated liver cirrhosis. Conducted across ...

The objective was to assess the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin 10/20 mg (EZ/S) vs doubling the baseline statin dose (to simvastatin ...

Introduction Though the efficacy on traditional lipid parameters of simvastatin/ezetimibe and atorvastatin has been studied extensively, ApoB/ApoA1 ratio which has better predictive value for ...

Please provide your email address to receive an email when new articles are posted on . High-intensity statin therapy may increase bleeding risk after minor stroke. Statin dose, moderate or high, did ...

Corn G, Melbye M, Hlatky MA, Wohlfahrt J, Lund M. A nationwide register-based cohort study was conducted in Denmark from 2008 to 2018 in 82,958 patients. Statins were limited to simvastatin single ...

Simvastatin plus rifaximin did not reduce progression to acute-on-chronic liver failure, complications from cirrhosis or risk for death in patients with decompensated cirrhosis, according to data ...